
Join All of Us and Help Make Medicine...
The All of Us research program, sponsored by the National Institutes of Health (NIH), is an ambitious, nationwide effort to find better...
Long-term, prospective, observational, multinational, parallel-cohort study monitoring safety in patients with MS newly started with fingolimod once daily or treated with another approved disease-modifying therapy.
The purpose of this world-wide prospective parallel-cohort study in patients with relapsing forms of MS, either newly treated with fingolimod or receiving another disease-modifying therapy, is to further explore the incidence of selected safety- related outcomes and to further monitor the overall safety profile of fingolimod under conditions of routine medical practice.
Contact Diane Kirk, RN at 508-368-3929 for more information.
For more information about this study: